Atack John R, Scott-Stevens Paul, Beech John S, Fryer Tim D, Hughes Jessica L, Cleij Marcel C, Baron Jean-Claude, Clark John C, Hargreaves Richard J, Aigbirhio Franklin I
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, United Kingdom.
J Pharmacol Exp Ther. 2007 Mar;320(3):1030-7. doi: 10.1124/jpet.106.114884. Epub 2006 Dec 12.
The occupancy by lorazepam of the benzodiazepine binding site of rat brain GABA(A) receptors was compared when measured using either in vivo binding of [(3)H]flumazenil (8-fluoro 5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester) in terminal studies or [(11)C]flumazenil binding in anesthetized animals assessed using a small animal positron emission tomography (PET) scanner (micro-PET). In addition, as a bridging study, lorazepam occupancy was measured using [(3)H]flumazenil in vivo binding in rats anesthetized and dosed under micro-PET conditions. Plasma lorazepam concentrations were also determined, and for each occupancy method, the concentration required to produce 50% occupancy (EC(50)) was calculated because this parameter is independent of the route of lorazepam administration. For the in vivo binding assay, lorazepam was dosed orally (0.1-10 mg/kg), whereas for the micro-PET study, lorazepam was given via the i.v. route as a low dose (0.75 mg/kg bolus) and then a high dose (0.5 mg/kg bolus then 0.2 mg/ml infusion). The lorazepam plasma EC(50) in the [(11)C]flumazenil micro-PET study was 96 ng/ml [95% confidence intervals (CIs) = 74-124 ng/ml], which was very similar to the [(3)H]flumazenil micro-PET simulation study (94 ng/ml; 95% CI = 63-139 ng/ml), which in turn was comparable with the [(3)H]flumazenil in vivo binding study (134 ng/ml; 95% CI = 119-151 ng/ml). These data clearly show that despite the differences in dosing (i.v. in anesthetized versus orally in conscious rats) and detection (in vivo dynamic PET images versus ex vivo measurements in filtered and washed brain homogenates), [(11)C]flumazenil micro-PET produces results similar to [(3)H]flumazenil in vivo binding.
当使用[(3)H]氟马西尼(8 - 氟 - 5,6 - 二氢 - 5 - 甲基 - 6 - 氧代 - 4H - 咪唑并[1,5 - a][1,4]苯二氮䓬 - 3 - 羧酸乙酯)在终末研究中的体内结合,或使用小动物正电子发射断层扫描(PET)扫描仪(微型PET)评估麻醉动物体内[(11)C]氟马西尼结合来测量时,比较了大鼠脑γ - 氨基丁酸A(GABA(A))受体苯二氮䓬结合位点上劳拉西泮的占有率。此外,作为一项衔接性研究,在微型PET条件下对麻醉并给药的大鼠,使用[(3)H]氟马西尼体内结合来测量劳拉西泮占有率。还测定了血浆劳拉西泮浓度,并且对于每种占有率测量方法,计算产生50%占有率所需的浓度(EC(50)),因为该参数与劳拉西泮给药途径无关。对于体内结合测定,劳拉西泮经口给药(0.1 - 10 mg/kg),而对于微型PET研究,劳拉西泮通过静脉途径给药,低剂量为(0.75 mg/kg推注),然后高剂量为(0.5 mg/kg推注然后0.2 mg/ml输注)。[(11)C]氟马西尼微型PET研究中劳拉西泮的血浆EC(50)为96 ng/ml [95%置信区间(CI) = 74 - 124 ng/ml],这与[(3)H]氟马西尼微型PET模拟研究(94 ng/ml;95% CI = 63 - 139 ng/ml)非常相似,而后者又与[(3)H]氟马西尼体内结合研究(134 ng/ml;95% CI = 119 - 151 ng/ml)相当。这些数据清楚地表明,尽管给药方式(麻醉大鼠静脉给药与清醒大鼠经口给药)和检测方式(体内动态PET图像与过滤和洗涤后的脑匀浆的体外测量)存在差异,但[(11)C]氟马西尼微型PET产生的结果与[(3)H]氟马西尼体内结合相似。